6547
高端疫苗
+0.80 (+1.34%)60.502,486成交張數–本益比5.52股價淨值比0.00%殖利率2026-09-16資料日期
綜合損益表公開資訊觀測站申報原值 · 年度(第 4 季累計) · 每一格 = 該科目 ÷ 營業收入 · 未來期間為分析師共識預估(2026-09-09)
營業收入2025613年增 +1.2%
毛利率202559.5%最新一期
營業利益率2025-43.3%最新一期
每股盈餘2025-0.86
| 會計項目 | 走勢 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 預估 1 家 | 2027 預估 1 家 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業收入合計 | – | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 營業成本合計 | – | – | 33.6% | 29.7% | 158.2% | 40.9% | 34.5% | 40.5% | – | – | |
| 營業毛利（毛損） | – | 100.0% | 66.4% | 70.3% | -58.2% | 59.1% | 65.5% | 59.5% | 60.0% | 60.0% | |
| 營業毛利（毛損）淨額 | – | 100.0% | 66.4% | 70.3% | -58.2% | 59.1% | 65.5% | 59.5% | – | – | |
| 推銷費用 | – | – | 66.5% | 0.2% | 20.0% | 40.3% | 37.0% | 32.5% | – | – | |
| 管理費用 | – | 5919.6% | 732.7% | 4.3% | 30.4% | 22.2% | 15.9% | 15.1% | – | – | |
| 研究發展費用 | – | 48101.1% | 5905.6% | 36.4% | 312.3% | 308.1% | 36.6% | 55.2% | – | – | |
| 營業費用合計 | – | 54020.7% | 6704.8% | 40.9% | 362.6% | 370.6% | 89.5% | 102.8% | – | – | |
| 營業利益（損失） | – | -53920.7% | -6638.4% | 29.4% | -420.8% | -311.5% | -24.1% | -43.3% | 8.3% | 27.4% | |
| 利息收入 | – | – | 12.8% | 0.1% | 2.1% | 21.4% | 7.6% | 4.8% | – | – | |
| 其他收入 | – | 420.2% | 675.7% | 13.5% | 18.8% | 4.7% | 0.0% | 0.2% | – | – | |
| 其他利益及損失淨額 | – | 54.8% | 232.8% | 0.2% | 3.4% | -2.6% | 6.2% | -6.2% | – | – | |
| 財務成本淨額 | – | 1707.7% | 142.7% | 0.2% | 7.4% | 9.6% | 3.1% | 1.4% | – | – | |
| 營業外收入及支出合計 | – | -1232.7% | 778.7% | 13.6% | 16.9% | 13.9% | 10.8% | -2.6% | – | – | |
| 稅前淨利（淨損） | – | -55153.4% | -5859.7% | 43.0% | -403.9% | -297.7% | -13.3% | -45.9% | – | – | |
| 繼續營業單位本期淨利（淨損） | – | -55153.4% | -5859.7% | 43.0% | -403.9% | -297.7% | -13.3% | -45.9% | – | – | |
| 本期淨利（淨損） | – | -55153.4% | -5859.7% | 43.0% | -403.9% | -297.7% | -13.3% | -45.9% | – | – | |
| 透過其他綜合損益按公允價值衡量之權益工具投資未實現評價損益 | – | – | – | – | 22.5% | -13.9% | 10.9% | -19.6% | – | – | |
| 不重分類至損益之項目： | – | – | – | – | 22.5% | -13.9% | 10.9% | -19.6% | – | – | |
| 國外營運機構財務報表換算之兌換差額 | – | -11.6% | -1.9% | -0.0% | 0.1% | 0.0% | 0.0% | 0.0% | – | – | |
| 後續可能重分類至損益之項目： | – | -11.6% | -1.9% | -0.0% | 0.1% | 0.0% | 0.0% | 0.0% | – | – | |
| 其他綜合損益（淨額） | – | -11.6% | -1.9% | -0.0% | 22.6% | -13.9% | 10.9% | -19.6% | – | – | |
| 本期綜合損益總額 | – | -55165.0% | -5861.7% | 43.0% | -381.3% | -311.6% | -2.3% | -65.5% | – | – | |
| 母公司業主（淨利∕損） | – | -55153.4% | -5859.7% | 43.0% | -403.9% | -297.7% | -13.3% | -45.9% | 14.2% | 30.2% | |
| 母公司業主（綜合損益） | – | -55165.0% | -5861.7% | 43.0% | -381.3% | -311.6% | -2.3% | -65.5% | – | – | |
| 基本每股盈餘 | – | -354.5% | -31.4% | 0.2% | -1.2% | -0.9% | -0.0% | -0.1% | 0.0% | 0.1% | |
| 稀釋每股盈餘 | – | -354.5% | – | 0.2% | -1.2% | – | – | -0.1% | – | – | |
| 繼續營業單位淨利（淨損） | – | -0.4% | -0.0% | 0.0% | -0.0% | – | – | – | – | – |
金額為公司申報原值除以一千(百萬元,四捨五入),每股金額為元。年度為第 4 季的年初至今累計數。最右邊的預估欄是分析師共識預估(2026-09-09),營收、營業利益、母公司淨利、每股盈餘直接取共識平均,毛利由共識營收乘上共識毛利率推算,不是公司財測。走勢條是歷史各期的相對大小,藍為正、綠為負。年增以去年同期為基期,基期非正數或變動超過十倍時不列。 權益變動表在申報資料分頁。